BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop

BioXcel Therapeutics has reported “promising” top-line data including an “encouraging” response rate in its phase 2 Keytruda combination clinical trial. What is promising and encouraging about the data? That remains under wraps, with the biotech opting against providing even a smidgen of information ahead of the presentation of the full data next month.